Evidence map›Paper›PMID 36452318›Full record

ArticleFrontiers in endocrinology2022

Genetic regulation of

Yaqi Li, Chunmei Gong, Yuanfei Xu, Xiongshun Liang, Xiaoping Chen, Wenxu Hong, Junxia Yan

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yaqi LiDepartment of Epidemiology and Health Statistics, XiangYa School of Public Health, Central South University, Changsha, Hunan, China.
Chunmei GongAnimal Laboratory, Shenzhen Center for Chronic Disease Control, Shenzhen, China.
Yuanfei XuAnimal Laboratory, Shenzhen Center for Chronic Disease Control, Shenzhen, China.
Xiongshun LiangCentral Laboratory, Shenzhen Center for Chronic Disease Control, Shenzhen, China.
Xiaoping ChenInstitute of Clinical Pharmacology, Central South University, Changsha, China.
Wenxu HongCentral Laboratory, Shenzhen Center for Chronic Disease Control, Shenzhen, China.
Junxia YanDepartment of Epidemiology and Health Statistics, XiangYa School of Public Health, Central South University, Changsha, Hunan, China.
Shenzhen Nanshan Center for Chronic Disease Control · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic retinopathy (DR) is a common and serious microvascular complication of diabetes mellitus (DM), but its pathological mechanism, especially the formation mechanism of new blood vessels remains unclear. Thrombospondin-1 ( Methods: Patients diagnosed with DR and DM patients without retinal problems were included in the case-control study. DNA methylation detection of Results: 150 patients diagnosed with DR and 150 DM patients without retinal complications were enrolled in the first recruitment, seven DR patients and seven DM patients were enrolled in the second recruitment. The patients with DR showed promoter hypomethylation of Conclusion:

Indexed as

Diabetes MellitusDiabetic RetinopathyCase-Control StudiesDNA MethylationHumansProtein Processing, Post-TranslationalRNA, MessengerThrombospondin 1RNA, MessengerThrombospondin 1thrombospondin-1, humandiabetic retinopathyDNA methylationgenetic regulationmeQTLTHBS1

Identifiers

PMID36452318
PMCPMC9702561
OpenAlexW4308974858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.